179 related articles for article (PubMed ID: 22188361)
1. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins.
Khrunin A; Ivanova F; Moisseev A; Khokhrin D; Sleptsova Y; Gorbunova V; Limborska S
Pharmacogenomics; 2012 Jan; 13(2):171-8. PubMed ID: 22188361
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
Khrunin AV; Moisseev A; Gorbunova V; Limborska S
Pharmacogenomics J; 2010 Feb; 10(1):54-61. PubMed ID: 19786980
[TBL] [Abstract][Full Text] [Related]
3. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
5. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
6. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.
Duran G; Aguín S; Cruz R; Barros F; Giráldez JM; Bernárdez B; López-López R; Carracedo Á; Lamas MJ
Head Neck; 2019 Aug; 41(8):2704-2715. PubMed ID: 30973677
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.
Lv H; Han T; Shi X; Yao Y; Yao Y; Qiu W; Yue L; Liang J
Med Oncol; 2014 Aug; 31(8):86. PubMed ID: 24958519
[TBL] [Abstract][Full Text] [Related]
8. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Xu Q; Ding YY; Song LX; Xu JF
Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
[TBL] [Abstract][Full Text] [Related]
9. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.
Beeghly A; Katsaros D; Chen H; Fracchioli S; Zhang Y; Massobrio M; Risch H; Jones B; Yu H
Gynecol Oncol; 2006 Feb; 100(2):330-7. PubMed ID: 16199080
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphisms of the CYP450 1A1, CYP450 2E1, GSTM1, GSTT1, and GSTP1 in Korean].
Xu QS; Hong YC; Lee KH
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Jun; 22(3):347-9. PubMed ID: 15952134
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
Yang LM; Li XH; Bao CF
Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
[TBL] [Abstract][Full Text] [Related]
12. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
Inada M; Sato M; Morita S; Kitagawa K; Kawada K; Mitsuma A; Sawaki M; Fujita K; Ando Y
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):729-34. PubMed ID: 20979931
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population.
Rossini A; Rapozo DC; Soares Lima SC; Guimarães DP; Ferreira MA; Teixeira R; Kruel CD; Barros SG; Andreollo NA; Acatauassú R; Matos HJ; Albano RM; Pinto LF
Carcinogenesis; 2007 Dec; 28(12):2537-42. PubMed ID: 17916905
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients from Yakutia].
Кhokhrin DV; Khrunin AV; Ivanova FG; Moiseev AA; Gorbunova VA; Limborskaia SA
Mol Gen Mikrobiol Virusol; 2013; (4):6-9. PubMed ID: 24645271
[TBL] [Abstract][Full Text] [Related]
15. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Krivak TC; Darcy KM; Tian C; Armstrong D; Baysal BE; Gallion H; Ambrosone CB; DeLoia JA;
J Clin Oncol; 2008 Jul; 26(21):3598-606. PubMed ID: 18640939
[TBL] [Abstract][Full Text] [Related]
16. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of CYP2E1 and GSTP1 in a South Indian population--comparison with North Indians, Caucasians and Chinese.
Soya SS; Padmaja N; Adithan C
Asian Pac J Cancer Prev; 2005; 6(3):315-9. PubMed ID: 16235992
[TBL] [Abstract][Full Text] [Related]
19. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
20. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients.
Ott K; Lordick F; Becker K; Ulm K; Siewert J; Höfler H; Keller G
Int J Colorectal Dis; 2008 Aug; 23(8):773-82. PubMed ID: 18443805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
